Skip navigation

Biopharma & Research Solutions

Build early evidence of therapy efficacy, enroll patients most likely to benefit from treatment, and leverage data-driven trial designs to accelerate your drug development1-5.

Accelerate drug development in earlier treatment settings

Natera Oncology Real-World Data (RWD) Solutions is a comprehensive, multimodal clinicogenomics data platform that enables drug developers to:

  • Identify higher risk populations for earlier intervention

  • Assess treatment response and disease progression quantitatively

A multi-modal and longitudinal database

alt text

Example: Mapping the patient journey

Figure 1: ctDNA kinetics in a patient with POLE-mutant colorectal cancer9

Figure 2: Example patient overview plot depicting treatment regimens, longitudinal ctDNA analysis, and imaging

Broad representation across tumor types & stages

100K+ patients

Rapid growth driven by Medicare and commercial reimbursement across:

  • Colorectal cancer
  • Breast cancer
  • Bladder cancer
  • Immunotherapy monitoring

Diverse representation across early and late stage cancers

Comprehensive suite of product and services

alt text

How can Signatera™ support your clinical trials?

Contact us to learn more

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.


1Kotani D, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nature Medicine. 2023

2Powles T, Assaf ZA, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021

3Coombes C, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research. 2019

4Magbanua MJM, Swigart LB, Wu H-T, et al. Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival. Annals of Oncology. 2021

5Abbosh C, Birkbak N, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017

6Oki E, Kotani D, Nakamura Y, et al. Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan. ASCO, Chicago, IL. June 2-6, 2023.

7Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 2020.

8Magbanua MJM, Swigart LB, Ahmed Z, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41(6):1091-1102.

9Lutfi A, Afghan MK, Kasi PM (August 12, 2023) Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy. Cureus 15(8): e43391. doi:10.7759/cureus.43391

icon-angle icon-bars icon-times